Safe and Timely Antithrombotic Removal (STAR) Registry

Condition(s) studied

Investigational drug(s) / intervention(s)

CytoSorb: Sorbent hemoperfusion system

Study summary

This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.

Eligibility

Primary outcome measure(s)

• Bleeding complications including requirements for transfusions and other blood products — Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 days

Trial sites (30)

Other trials for the same condition